Cleared Traditional

FLEXION DISTRATION SUPPORT (K921711) - FDA 510(k) Clearance

Class I Physical Medicine device.

K921711 · Altoona Medical Supply · Physical Medicine device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1992
Decision
96d
Days
Class 1
Risk

K921711 is an FDA 510(k) clearance for the FLEXION DISTRATION SUPPORT. Classified as Accessories, Traction (product code ILZ), Class I - General Controls.

Submitted by Altoona Medical Supply (Altoona, US). The FDA issued a Cleared decision on July 13, 1992 after a review of 96 days - within the typical 510(k) review window.

This device falls under the Physical Medicine FDA review panel, regulated under 21 CFR 890.5925 - the FDA physical medicine device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Physical Medicine review framework, consistent with the majority of Class II 510(k) submissions.

View all Altoona Medical Supply devices

Submission Details

510(k) Number K921711 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 08, 1992
Decision Date July 13, 1992
Days to Decision 96 days
Submission Type Traditional
Review Panel Physical Medicine (PM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
19d faster than avg
Panel avg: 115d · This submission: 96d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code ILZ Accessories, Traction
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 890.5925
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.